Skip to main content

Table 1 Clinical, serological, and immunological features of the patient cohort at baseline and after treatment with glucocorticoids

From: Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse

 

Patients with IgG4-RD before GC (n = 30)

Healthy control subjects (n = 20)

p Value

Patients with IgG4-RD after GC (n = 30)

p Value

Definite IgG4-RD, n (%)

29 (97%)

    

Probable IgG4-RD, n (%)

1 (3%)

    

Possible IgG4-RD, n (%)

0 (0%)

    

Age, yr, median

70 (58–73)

54 (46–65)

0.005

  

Male sex, n (%)

23 (77%)

12 (60%)

   

ESR (0–20 mm/h)

18 (10–35)

    

CRP (< 6 mg/L)

5 (2–6)

    

IgG4-RD RI (0–3)

6 (6–9)

  

2 (1–2.25)

0.0001

Serum IgG4 (< 135 mg/dl)

313 (206–507)

  

191 (87–230)

0.0001

CD19+ B cells (cells/ml)

162,000 (105,750–217,750)

236,000 (200,000–299,000)

0.0002

163,500 (100,750–233,500)

0.131

CD20+ B cells (cells/ml)

144,500 (93,000–201,700)

224,000 (199,000–279,000)

0.0001

150,500 (85,500–226,250)

0.1

Naive B cells (cells/ml)

15,120 (8895–29,140)

23,810 (17,930–54,020)

0.01

7485 (4195–14,018)

0.0001

Percentage of CD19+ B cells

10.55 (7.94–15.49)

13.02 (7.89–19.39)

0.35

4.78 (3.14–8.33)

0.0001

Memory B cells (cells/ml)

26,475 (13,040–55,450)

37,170 (21,900–57,190)

0.25

41,800 (21,148–69,435)

0.026

Percentage of CD19+ B cells

18.5 (9.26–27.31)

16.60 (9.18–26.34)

0.62

22.89 (11.14–32.50)

0.028

Plasmablasts (cells/ml)

2515 (1023–5550)

340 (170–600)

0.0001

270 (210–1198)

0.0001

Percentage of CD19+ B cells

1.25 (0.6–4.51)

0.19 (0.05–0.29)

0.0001

0.23 (0.1–0.79)

0.0001

Plasma cells (cells/ml)a

278 (0–1332)

0 (0–0)

0.0005

55 (0–423)

0.0006

Percentage of CD19+ B cellsa

0.23 (0–1.27)

0 (0–0)

0.0001

0.07 (0–0.64)

0.0008

Organ involvement, n (%)

 Pancreas

20 (66%)

    

 Aorta and retroperitoneum

7 (23.3%)

    

 Lymph nodes

5 (16.6%)

    

 Biliary tree

5 (16.6%)

    

 Salivary glands

2 (6.6%)

    

 Lacrimal glands

2 (6.6%)

    

 Lung

2 (6.6%)

    

 Orbit

1 (3.3%)

    

 Nasal sinuses

1 (3.3%)

    

 Meninges

1 (3%)

    

 Kidney

1 (3.3%)

    
  1. Abbreviations: CRP C-reactive protein, ESR Erythrocyte sedimentation rate, IgG4-RD RI IgG4-related disease responder index, GC Glucocorticoids
  2. Results are expressed as median (IQR), except where indicated otherwise
  3. a Results expressed as mean (range)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us